Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Impact of abciximab on prognosis in diabetic patients undergoing primary percutaneous coronary intervention.

Perkan A, Vitrella G, Barbati G, De Monte A, D'Agata B, Merlo M, Giannini F, Della Grazia E, Rakar S, Salvi A, Igidbashian D, Morgera T, Zalukar W, Sinagra G.

J Cardiovasc Med (Hagerstown). 2013 Feb;14(2):127-35. doi: 10.2459/JCM.0b013e32834eec7a.

PMID:
22343257
2.

Effects of baseline coronary occlusion and diabetes mellitus in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Piccolo R, Galasso G, Iversen AZ, Eitel I, Dominguez-Rodriguez A, Gu YL, de Smet BJ, Mahmoud KD, Abreu-Gonzalez P, Trimarco B, Thiele H, Piscione F.

Am J Cardiol. 2014 Oct 15;114(8):1145-50. doi: 10.1016/j.amjcard.2014.07.030. Epub 2014 Jul 30.

PMID:
25193670
3.

Abciximab reduces mortality in diabetics following percutaneous coronary intervention.

Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ.

J Am Coll Cardiol. 2000 Mar 15;35(4):922-8.

4.

[Does abciximab improve the prognosis of diabetics after percutaneous coronary intervention?].

Hernández García JM, Domínguez Franco A, Jiménez-Navarro MF, Alonso Briales JH, Curiel Balsera E, Gómez Doblas JJ, De Teresa Galván E.

Rev Esp Cardiol. 2002 Aug;55(8):810-5. Spanish.

5.

Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.

Kleiman NS, Lincoff AM, Kereiakes DJ, Miller DP, Aguirre FV, Anderson KM, Weisman HF, Califf RM, Topol EJ.

Circulation. 1998 May 19;97(19):1912-20.

6.

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB, Moses JW, Moliterno DJ, Effron MB, Topol EJ.

Circulation. 1998 Aug 25;98(8):734-41.

7.

Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial).

Stuckey TD, Stone GW, Cox DA, Tcheng JE, Garcia E, Carroll J, Guagliumi G, Rutherford BD, Griffin JJ, Turco M, Lansky AJ, Mehran R, Fahy M, Brodie BR, Grines CL; CADILLAC investigators.

Am J Cardiol. 2005 Jan 1;95(1):1-7.

PMID:
15619385
8.

Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial).

Maioli M, Bellandi F, Leoncini M, Toso A, Dabizzi RP.

J Am Coll Cardiol. 2007 Apr 10;49(14):1517-24. Epub 2007 Mar 26.

9.

Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.

Mehilli J, Kastrati A, Schühlen H, Dibra A, Dotzer F, von Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger PP, Schömig A; Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators.

Circulation. 2004 Dec 14;110(24):3627-35. Epub 2004 Nov 7.

10.

Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial).

Nikolsky E, Grines CL, Cox DA, Garcia E, Tcheng JE, Sadeghi M, Mehran R, Lansky AJ, Na Y, Stone GW.

Am J Cardiol. 2007 Apr 15;99(8):1055-61. Epub 2007 Mar 6.

PMID:
17437727
11.

Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up.

Roffi M, Moliterno DJ, Meier B, Powers ER, Grines CL, DiBattiste PM, Herrmann HC, Bertrand M, Harris KE, Demopoulos LA, Topol EJ; TARGET Investigators.

Circulation. 2002 Jun 11;105(23):2730-6.

12.

Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial.

Nikolsky E, Aymong ED, Halkin A, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Cohen DA, Negoita M, Lansky AJ, Stone GW.

J Am Coll Cardiol. 2004 Aug 4;44(3):547-53.

13.

Left ventricular function after ST-elevation myocardial infarction in patients treated with primary percutaneous coronary intervention and abciximab or tirofiban (from the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial).

Taglieri N, Saia F, Guiducci V, Tondi S, Conrotto F, Marrozzini C, Rocchi G, Biagini E, Reggiani ML, Giacometti P, Piovaccari G, Manari A, Marzocchi A; FATA Trial Investigators.

Am J Cardiol. 2009 Mar 15;103(6):785-90. doi: 10.1016/j.amjcard.2008.11.029. Epub 2009 Jan 21.

PMID:
19268732
14.

Early abciximab administration before primary percutaneous coronary intervention improves clinical outcome in diabetic patients with ST-segment elevation myocardial infarction (EUROTRANSFER Registry).

Dziewierz A, Mielecki W, Siudak Z, Rakowski T, Janzon M, Birkemeyer R, Zasada W, Dubiel JS, Dudek D.

Atherosclerosis. 2012 Jul;223(1):212-8. doi: 10.1016/j.atherosclerosis.2012.04.018. Epub 2012 May 15.

PMID:
22658254
15.

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.

Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, Demopoulos L; TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial.

N Engl J Med. 2001 Jun 21;344(25):1888-94.

16.

Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.

Marso SP, Lincoff AM, Ellis SG, Bhatt DL, Tanguay JF, Kleiman NS, Hammoud T, Booth JE, Sapp SK, Topol EJ.

Circulation. 1999 Dec 21-28;100(25):2477-84.

17.

Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.

Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW; CADILLAC Investigators.

Circulation. 2003 Sep 16;108(11):1316-23. Epub 2003 Aug 25.

18.

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.

Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ.

Circulation. 1999 Apr 20;99(15):1951-8.

19.
20.

Use of glycoprotein IIb/IIIa inhibitors in invasively-treated patients with non-ST elevation acute coronary syndrome.

De Servi S, Mariani M, Vandoni P, Dellavalle A, Politi A, Poletti F, Bonizzoni E, Leoncinie M; Registro Osservazionale Angina Instabile (ROSAI-2) Investigators.

J Cardiovasc Med (Hagerstown). 2006 Mar;7(3):159-65.

PMID:
16645379

Supplemental Content

Support Center